drugset / Trial / NCT00882583
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Phase 1
Terminated
22 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT in Cohort B
Timeline
- Start
- 2009-07
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | dasatinib anhydrous | Small molecule | — | Oral |
| Background | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |